Your browser doesn't support javascript.
loading
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).
Zhang, Jia-Tao; Dong, Song; Gu, Wei-Quan; Zhao, Ning; Liang, Yi; Tang, Wen-Fang; Liu, Shuo-Yan; Wang, Feng; Wang, Guang-Suo; Peng, Bin; Wu, Nan; Yan, Shi; Geng, Guo-Jun; Xie, Ze-Feng; Yang, Yan-Long; Zhang, Jian-Hua; Zhang, Tao; Yang, Nuo; Jiao, Wen-Jie; Xiong, Yuan-Yuan; Cai, Miao; Li, Fang; Chen, Rong-Rong; Yan, Hong-Hong; Maggie Liu, Si-Yang; Yi, Xin; Zhong, Wen-Zhao; Yang, Xue-Ning; Wu, Yi-Long.
Afiliação
  • Zhang JT; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Dong S; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Gu WQ; Department of Thoracic Surgery, The First People's Hospital of Foshan, Guangdong, China.
  • Zhao N; Department of Thoracic Surgery, The First People's Hospital of Foshan, Guangdong, China.
  • Liang Y; Department of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.
  • Tang WF; Department of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, China.
  • Liu SY; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
  • Wang F; Department of Thoracic Oncology Surgery, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
  • Wang GS; Department of Thoracic Surgical, Shenzhen People's Hospital, Shenzhen, China.
  • Peng B; Department of Thoracic Surgical, Shenzhen People's Hospital, Shenzhen, China.
  • Wu N; Department of Thoracic Surgery II, Peking University Cancer Hospital and Institute, Beijing, China.
  • Yan S; Department of Thoracic Surgery II, Peking University Cancer Hospital and Institute, Beijing, China.
  • Geng GJ; Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen Fujian, China.
  • Xie ZF; Thoracic Surgical Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Yang YL; Department of Cardiothoracic Surgery, Shantou Central Hospital, Shantou, China.
  • Zhang JH; Department of Thoracic Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
  • Zhang T; Department of Thoracic Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
  • Yang N; Department of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
  • Jiao WJ; Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Xiong YY; Geneplus-Beijing Institute, Beijing, China.
  • Cai M; Geneplus-Beijing Institute, Beijing, China.
  • Li F; Geneplus-Beijing Institute, Beijing, China.
  • Chen RR; Geneplus-Beijing Institute, Beijing, China.
  • Yan HH; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Maggie Liu SY; Department of Hematology, First Affiliated Hospital, Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, Guangdong, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou, Guangdong, China.
  • Yi X; Geneplus-Beijing Institute, Beijing, China.
  • Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Yang XN; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou, Guangdong, China. Electronic address: syylwu@live.cn.
Clin Lung Cancer ; 25(1): e1-e4, 2024 01.
Article em En | MEDLINE | ID: mdl-37880076
BACKGROUND: The utility of circulating tumor DNA to monitor molecular residual disease (MRD) has been clinically confirmed to predict disease recurrence in non-small cell lung cancer (NSCLC) patients after radical resection. Patients with longitudinal undetectable MRD show a favorable prognosis and might not benefit from adjuvant therapy. PATIENTS AND METHODS: The CTONG 2201 trial is a prospective, multicenter, single-arm study (ClinicalTrials.gov identifier, NCT05457049), designed to evaluate the hypothesis that no adjuvant therapy is needed for patients with longitudinal undetectable MRD. Pathologically confirmed stage IB-IIIA NSCLC patients who have undergone radical resection will be screened. Only patients with 2 consecutive rounds of undetectable MRD will be enrolled (first at days 3-10, second at days 30 ± 7 after surgery), and admitted for imaging and MRD monitoring every 3 months without adjuvant therapy. The primary endpoint is the 2-year disease-free survival rate for those with longitudinal undetectable MRD. The recruitment phase began in August 2022 and 180 patients will be enrolled. CONCLUSIONS: This prospective trial will contribute data to confirm the negative predictive value of MRD on adjuvant therapy for NSCLC patients. CLINICAL TRIAL REGISTRATION: NCT05457049 (CTONG 2201).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article